Reading an FDA warning letter: record volumes, familiar failures

The US Food and Drug Administration (FDA) publishes almost every stage of its manufacturing enforcement process, from inspection outcomes to the letters themselves. The databases are free, searchable and updated continuously. Read together, they show an agency that keeps finding the same small set of faults, in places that do not always match assumptions.

The sequence begins with an inspection. Where investigators observe conditions that may breach the Federal Food, Drug, and Cosmetic Act, they issue a Form 483 listing observations ranked by risk significance. FDA is explicit that a 483 is not a final compliance determination. The firm responds, and the agency then classifies the inspection.